Search for: "United States v. LaRoche"
Results 1 - 20
of 42
Sorted by Relevance
|
Sort by Date
12 Apr 2014, 6:39 am
Hoffman-LaRoche and Genentech cases on BonivaHoffman-LaRoche lost its appeal at the CAFC:Plaintiff Hoffmann-La Roche, Inc., (“Roche”) appealsfrom the decision of the United States District Court forthe District of New Jersey granting the defendant genericdrug companies summary judgment of invalidity as toclaims 1-8 of U.S. [read post]
17 Jan 2003, 3:24 pm
Read Empagran v. [read post]
18 Feb 2021, 6:12 pm
On February 17, 2021, the district court issued a new order in the continuing saga of United States v. [read post]
12 May 2010, 12:05 pm
’” Hoffman-LaRoche, Inc. v. [read post]
10 Jul 2010, 3:57 am
Despite public outcry, and the urging of physicians, asbestos is still not banned in the United States. [read post]
8 Feb 2017, 11:35 am
LaRoche v. [read post]
2 Nov 2006, 8:11 am
Celotex Corp. v. [read post]
25 Jun 2013, 9:52 am
Hoffman LaRoche Ltd. v. [read post]
6 Nov 2014, 5:00 am
To construe “these four puzzling opinions that have few common aspects,” Tyree employed the analysis for such situations adopted by the United States Supreme Court in Marks v. [read post]
15 Oct 2008, 5:11 pm
United States v. [read post]
10 Oct 2008, 11:32 am
You can separately subscribe to the Pharma & Biotech edition of the IP Thinktank Global Week in Review by subscribing by email, or selecting ‘all posts’ or ‘Pharma, Biotech & Chem’ for the RSS option at the Subscribe page: [duncanbucknell.com] Highlights this week included: Mircera (Methoxy polyethylene glycol-epoetin beta) - US: Trial judge grants permanent injunction in case relating to recombinant erythropoietin (EPO) patent: Amgen… [read post]
12 Oct 2011, 8:31 am
Pylon was a permanent injunction:Robert Bosch LLC (“Bosch”) appeals from the order of the United States District Court for the District of Delaware, denying Bosch’s post-trial motion for entry of a permanent injunction. [read post]
29 Nov 2012, 1:23 pm
[T]he United States [FDA] requires the tablet manufacturers . . . to account for and warn of a drug’s properties. [read post]
6 Nov 2008, 4:49 pm
Hoffmann-LaRoche, Ltd., 368 U.S. [read post]
7 Mar 2007, 11:09 am
Hoffmann-Laroche, Ltd., 417 F.3d 1267, 1271 (D.C. [read post]
22 Feb 2011, 7:02 am
United States, 449 U.S. 383, 389, 101 S. [read post]
5 Jul 2007, 10:37 am
United States, 740 F.2d 1428, 1440 (8th Cir. 1984); Madsen v. [read post]
2 Jun 2011, 12:46 pm
Hoffmann-LaRoche, Inc., 540 So.2d 102, 104 (Fla. 1989). [read post]
11 Apr 2014, 11:29 am
Finally, United States Patent No. 6,468,559 (“Chen”) […] disclosed a preferred embodiment in which “a dosage form of the invention is administered to a patient . . . preferably once a month. [read post]
18 Apr 2013, 7:39 am
By a tight five-to-four decision, the United States Supreme Court's Genesis Health Care Corp. v. [read post]
